Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- Acronyms TRAVERSE
- Sponsors AbbVie
- 16 Nov 2018 Planned End Date changed from 5 Jun 2022 to 30 Jun 2022.
- 16 Nov 2018 Planned primary completion date changed from 5 Jun 2022 to 30 Jun 2022.
- 11 May 2018 New trial record